Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics is a clinical-stage biopharmaceutical company with a lead product candidate, oral (Z)-endoxifen, being evaluated for the treatment and prevention of breast cancer and other indications. While the company does not generate revenue yet, we believe that strong results or milestones from its various clinical trials over the next year could act as strong catalysts and drive the stock price. Furthermore, Atossa's proprietary form of Endoxifen shows potential in multiple settings and the recent appointment of a new CFO with extensive finance experience in global life-science businesses could benefit the company's financial management. However, there are risks to reaching a specific price target, including balance sheet/liquidity risks, failure of clinical trials, and competition.

Bears say

Atossa Therapeutics is facing multiple risks as they continue to conduct clinical trials for their lead product candidate, (Z)-endoxifen. These risks include potential balance sheet and liquidity issues, failure to gain regulatory approvals and suitable reimbursement, competition, and changing macroeconomic factors. Additionally, the company's current valuation may be attractive to some investors, but it is based on a NPV analysis and does not take into account the high risks associated with Atossa's operations. Overall, the company faces significant risks and their success in clinical trials, gaining regulatory approvals, and commercializing their products will be key factors in determining their future growth and potential upside for investors.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.